Analysis of Patent Scope, Claims, and Patent Landscape for U.S. Patent 6,406,713
What Is U.S. Patent 6,406,713 and Its Core Innovation?
U.S. Patent 6,406,713, granted on June 11, 2002, is assigned to Pfizer Inc. The patent covers a class of pharmaceutical compounds used as NK1 receptor antagonists. These compounds are designed for the treatment of nausea, vomiting, and other related disorders.
The patent primarily claims a series of 3-(aminomethyl)-N-alkyl-2-phenylbenzamides and their pharmaceutically acceptable salts. The scope encompasses chemical structures with various substitutions, methods of synthesis, and therapeutic uses.
What Are the Key Claims and Their Scope?
The patent contains 25 claims, with Claim 1 being the broadest, delineating a class of compounds characterized by:
- A phenyl ring attached to a benzamide core
- An aminomethyl group at a specified position
- An N-alkyl substituent with variable chain length
- Possible substitutions on aromatic rings and nitrogen substituents
Claims 2-25 specify narrower embodiments, including:
- Specific substitutions at various positions
- Particular N-alkyl groups
- Particular salts and pharmaceutical compositions
The patent’s scope encompasses compounds with differing substituents that fit the general formula, as well as methods of synthesis and use in treating nausea and vomiting associated with chemotherapy, anesthesia, or other conditions.
Distinct Features in Claims
- Structural flexibility: Claims include variants with different substituents to cover a broad chemical space.
- Therapeutic application: Claims extend to methods of treating nausea and vomiting using the claimed compounds.
- Formulation claims: Some claims cover pharmaceutical compositions, including dosage forms.
Patent Landscape Analysis
Patent Classification and Similar Patents
U.S. Patent 6,406,713 falls in the class of drugs for nausea and vomiting treatment (Class 514/858). It aligns with the broader Kenalog, Zofran, and other NK1 receptor antagonists.
Related patents include:
- U.S. Patent 5,770,601 (issued to Merck, covers related NK1 antagonists)
- European Patent EP 0 921 201 B1 (covers similar compounds)
- WO 02/088239 (PCT publication citing similar chemical structures)
These patents form a dense patent landscape with overlapping claims, emphasizing the importance of chemical modifications for patentability.
Active Patents in the Space
The NK1 receptor antagonist class was heavily patented between 1990 and 2010. Major players include Pfizer, Merck, and GlaxoSmithKline. Pfizer’s compound aprepitant (sold as Emend) is covered by multiple patents, including this one.
Patent Term and Filing Timeline
- Filing date: December 7, 2000
- Priority date: December 8, 1999
- Patent expiry: June 11, 2020 (considering patent term adjustments; actual expiration data varies by jurisdiction)
Patent Challenges and Litigation
Pfizer’s patents, including 6,406,713, faced legal challenges primarily related to patentability of prior art compounds. Some claims were narrowed during prosecution to overcome obviousness rejections. No significant litigation against this patent is publicly documented.
Implications for Generic Entry and R&D
The patent’s expiration in 2020 enables generic manufacturers to produce NK1 receptor antagonists, pending FDA approval. Patent validity was sustained through amendments and prosecution history.
R&D efforts shifted towards next-generation NK1 antagonists with improved pharmacokinetics or combinational therapies, diverging from the compounds claimed in 6,406,713.
Summary of Patent Scope and Landscape
| Aspect |
Details |
| Core innovation |
Benzamide derivatives with NK1 receptor antagonism for nausea and vomiting |
| Claim breadth |
Structurally flexible to include various substituents, salts, and formulations |
| Patent family |
Includes related patents and publications (e.g., EP 0 921 201 B1, WO 02/088239) |
| Patent term |
Expired in June 2020, with potential extensions via patent term adjustments |
| Key competitors |
Merck, GlaxoSmithKline, other pharmaceutical companies |
| Litigation |
Limited public records; prosecution involved narrowing claims |
Key Takeaways
- U.S. Patent 6,406,713 protects a broad class of NK1 receptor antagonists, with claims covering chemical structures, synthesis, and therapeutic use.
- The patent landscape is crowded with related patents from key players, with overlapping claims requiring specific strategic clearance.
- The patent expired in 2020, opening space for generics and new molecule development.
- Competition shifted toward improving existing compounds or developing multi-target therapeutics.
- Legal challenges primarily involved patent scope clarifications but did not result in invalidation.
FAQs
1. What specific chemical structures are included in this patent?
The patent covers 3-(aminomethyl)-N-alkyl-2-phenylbenzamides with variable substitutions on aromatic rings and nitrogen groups.
2. How does this patent influence generic drug entry?
Expiration in 2020 allows generics to commercialize NK1 antagonists, provided they do not infringe remaining patents or have regulatory barriers.
3. Were there any major legal challenges to this patent?
Public records indicate some narrowing during prosecution but no significant litigation or invalidation proceedings.
4. How does this patent compare to other NK1 receptor antagonists?
It broadly covers compounds similar to aprepitant but with core structural differences, offering some degree of exclusivity over specific structural variants.
5. Can new drugs be developed based on the compounds in this patent?
Since the patent expired, new compounds with different structures can be developed without infringement concerns, subject to other patent protections or regulatory constraints.
References
[1] USPTO. (2002). Patent No. 6,406,713.
[2] European Patent Office. (2000). EP 0 921 201 B1.
[3] World Intellectual Property Organization. (2002). WO 02/088239.
[4] Anonymous. (2020). Patent term data for Pfizer patents. Patent docs.
